<DOC>
	<DOCNO>NCT01609556</DOCNO>
	<brief_summary>The purpose study test IMGN853 patient FOLR-1 positive tumor .</brief_summary>
	<brief_title>First-in-Human Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Mirvetuximab Soravtansine Adults With Ovarian Cancer Other FOLR1-Positive Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Criteria Selection Patient Population Inclusion Criteria Patients advance solid tumor refractory standard treatment , standard treatment available , patient refuse standard therapy . â‰¥ 18 year old time inform consent . ECOG Performance Status 0 1 . Patients must adequate hematologic organ function . Patients must willing able sign inform consent form , follow study visit schedule protocol requirement . Women childbearing potential men must agree use effective contraceptive method study least twelve week last dose study drug . Women childbearing potential must negative pregnancy test prior first dose study treatment . Exclusion Criteria Grade &gt; 1 neuropathy Any active chronic corneal disorder Sjogren 's syndrome . Serious concurrent illness : Any concomitant anticancer treatment . Women childbearing potential pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>FOLR solid tumor</keyword>
</DOC>